γδ T Cells Engineering Services

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs is a world-renowned service provider for immunotherapy. We have experience in developing chimeric antigen receptor (CAR)-engineered T/NK/macrophage cell therapy. Gamma-delta (γδ) T cells are considered as promising candidates for developing cellular immunotherapy. With our expertise and experience in cellular immunotherapy development, we can help you design and develop γδ T cells.

Properties of γδ T Cells

γδ T cells are an important subset of "unconventional" T lymphocytes, occupying 1-10% of circulating T-cells. Unlike αβ T cells, they have the ability to recognize a broad range of antigens without the presence of major histocompatibility complex (MHC) molecules. Their activation is mediated by γδ T-cell receptor (TCR) and by activating receptors shared with NK cells (e.g., NKG2D and DNAM-1). Activated γδ T cells exhibit multiple effector functions, including cytotoxicity against tumor cells, cytokine and chemokine production, antigen-presenting functions and regulatory abilities. However, several other studies have shown that γδ T cells can also promote tumor progression by inhibiting anti-tumor response.

γδ T Cell Subsets

Human γδ cells are a minor population in peripheral blood but enriched in epithelial and mucosal tissues where they are thought to serve as the first line of defense against pathogenic challenge. Generally, human γδ T cells are divided into three structural subsets according to their TCR δ chain usage: Vδ1, Vδ2 and Vδ3 T cells. In peripheral blood of healthy human subjects, Vγ9Vδ2 T-cells can account for up 95% of γδ T-cells. Human γδ T cells play essential roles in the innate immunity response. Vγ9Vδ2 T cells induce monocyte differentiation into antigen-presenting cells through the release of IFN-γ, TNF-α, GM-CSF, and IL-4, as well as recruitment, activation, and differentiation of neutrophils.

Overview of γδ T cell functional programing in human. Fig.1 Overview of γδ T cell functional programing in human. (Nguyen, 2019)

Related Services

Sharing both innate and adaptive immune properties, γδ T cells are attractive candidates for cellular engineering. The disparate properties of γδ T cells to recognize antigens in MHC unrestricted manner bestow an advantage to γδ T cells over αβT cells for anti-tumor immunity. At present, many strategies have been developed to engineer γδ T cells for tumor therapy.

Fig.2 Different genetic engineering strategies for harnessing the anti-tumor activity of γδ T cells. (Morandi, 2020)

One-stop CAR-γδ T Cell Development Services

Since γδ T cells can be safely applied in the allogeneic setting and exhibit natural anti-tumor reactivity, arming γδ T cells with a CAR may provide a way to safely use allogeneic CARs and can potentially target minor clones with lower antigen density.

One-stop αβ TCR-γδ T Cell Development Services

Since the γ and δ TCR chains do not mispair with transferred α or β chains, human TCRs is to use γδ T cells as the substrate for gene transfer. TCR-based engineering methods include TCR gene transfer from αβ to γδ T cells and vice versa.

One-stop NKT TCR-γδ T Cell Development Services

iNKT cells share properties of both T cells and NK cells and the transfection of NKT cell TCR has the potential to be a new approach to tumor immunotherapy in patients with various types of cancer. iNKT TCR-transduced γδ T cells retain their γδ TCR expression and produce a bi-potential innate lymphocyte.

Creative Biolabs is committed to providing a range of γδ T cells engineering services. Our scientists are here to provide the guidance you need to steer you down the path of developing cutting-edge γδ T cell therapies. Please feel free to contact us with your requirements.

References

Nguyen, C.T.; et al. γδ T cells in rheumatic diseases: from fundamental mechanisms to autoimmunity//Seminars in immunopathology. Springer Berlin Heidelberg. 2019, 41(5): 595-605.
Morandi, F.; et al. Engineering the bridge between innate and adaptive immunity for cancer immunotherapy: focus on γδ T and NK cells. Cells. 2020, 9(8): 1757.